Literature DB >> 20841962

Metabolic syndrome and its potential effect on treatment response to aripiprazole: a post hoc analysis of the stabilization phase of a long-term, double-blind study in patients with bipolar disorder (CN138-010).

David E Kemp, James M Eudicone, Robert D McQuade, Jessie S Chambers, Ross A Baker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20841962      PMCID： PMC3904751          DOI： 10.1097/JCP.0b013e3181f0569f

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  12 in total

Review 1.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

Authors:  Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus; Fernando Costa
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

2.  Moderators of treatment outcomes: clinical, research, and policy importance.

Authors:  Helena C Kraemer; Ellen Frank; David J Kupfer
Journal:  JAMA       Date:  2006-09-13       Impact factor: 56.272

3.  Metabolic syndrome in patients with bipolar disorder.

Authors:  Andrea Fagiolini; Ellen Frank; Scott Turkin; Patricia R Houck; Isabella Soreca; David J Kupfer
Journal:  J Clin Psychiatry       Date:  2008-04       Impact factor: 4.384

4.  Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians.

Authors:  Andrea Fagiolini; Ellen Frank; John A Scott; Scott Turkin; David J Kupfer
Journal:  Bipolar Disord       Date:  2005-10       Impact factor: 6.744

5.  A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.

Authors:  Paul E Keck; Joseph R Calabrese; Robert D McQuade; William H Carson; Berit X Carlson; Linda M Rollin; Ronald N Marcus; Raymond Sanchez
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

6.  Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial.

Authors:  David E Kemp; Joseph R Calabrese; Quynh-Van Tran; Andrei Pikalov; James M Eudicone; Ross A Baker
Journal:  J Clin Psychiatry       Date:  2010-05-04       Impact factor: 4.384

7.  Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents.

Authors:  Dan W Haupt; Lisa C Rosenblatt; Edward Kim; Ross A Baker; Richard Whitehead; John W Newcomer
Journal:  Am J Psychiatry       Date:  2009-01-15       Impact factor: 18.112

8.  Translating scientific opportunity into public health impact: a strategic plan for research on mental illness.

Authors:  Thomas R Insel
Journal:  Arch Gen Psychiatry       Date:  2009-02

9.  Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.

Authors:  Paul E Keck; Joseph R Calabrese; Roger S McIntyre; Robert D McQuade; William H Carson; James M Eudicone; Berit X Carlson; Ronald N Marcus; Raymond Sanchez
Journal:  J Clin Psychiatry       Date:  2007-10       Impact factor: 4.384

10.  A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.

Authors:  John W Newcomer; Joao Alberto Campos; Ronald N Marcus; Christopher Breder; Robert M Berman; Wendy Kerselaers; Gilbert J L'italien; Marleen Nys; William H Carson; Robert D McQuade
Journal:  J Clin Psychiatry       Date:  2008-07       Impact factor: 4.384
View more
  2 in total

1.  Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder.

Authors:  S L McElroy; D E Kemp; E S Friedman; N A Reilly-Harrington; L G Sylvia; J R Calabrese; D J Rabideau; T A Ketter; M E Thase; V Singh; M Tohen; C L Bowden; E E Bernstein; B D Brody; T Deckersbach; J H Kocsis; G Kinrys; W V Bobo; M Kamali; M G McInnis; A C Leon; S Faraone; A A Nierenberg; R C Shelton
Journal:  Acta Psychiatr Scand       Date:  2015-06-26       Impact factor: 6.392

2.  Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies.

Authors:  Mehul Patel; Rakesh Jain; Mauricio Tohen; Vladimir Maletic; Willie R Earley; Lakshmi N Yatham
Journal:  Int Clin Psychopharmacol       Date:  2021-03-01       Impact factor: 2.023
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.